Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Proteomics has raised $3 million through a heavily oversubscribed share placement
  • The company will use its new cash to commercialise its diabetic kidney disease predictor, PromarkerD
  • The product boasts the ability to predict diabetic kidney disease up to four years in advance, meaning sufferers can take preemptive steps to minimise kidney damage
  • Proteomics shares are trading 4.35 per cent down in early afternoon trade, currently worth 33 cents each

Investors have touted confidence in Proteomics with a heavily oversubscribed share placement raising $3 million.

The medi-tech company is now set to issue 10.8 million shares at a nicely-discounted 28 cents apiece — a 13.9 per cent premium on Proteomics’ 20-day volume-weighted average share price.

Proteomics plans to use the new cash to fund the commercialisation of its PromarkerD diagnostic device and to develop its analytical services and intellectual property (IP).

PromarkerD is Proteomics’ diabetic kidney disease prediction test which, according to the company, is able to predict the disease up to four years in advance. This allows sufferers to take the preemptive steps necessary to minimise kidney damage and have a better quality of life.

With today’s funding, one of the highlights for spending is Proteomics’ attempt to secure a reimbursement code for PromarkerD in the U.S.

While the company didn’t provide details regarding the specifics of the code, reimbursement codes generally mean there will be a form of government subsidy for the commercialisation of the product. This new code would go hand-in-hand with the CE Mark certification received for the product earlier this week.

Proteomics International Managing Director Dr Richard Lipscombe said the company is in a strong position to tackle the new calendar year.

“The funds will be used to not only advance the commercialisation of PromarkerD, but to upgrade our facilities and accelerate the development of existing and potentially new IP,” Dr Richard said.

He said Proteomics is expecting 2020 to be a “transformative” year for the company.

The company announced to the ASX today that the successful capital raising means it has a strong balance sheet for any potential future licensing and even partnering discussions for PromarkerD.

Proteomics shares are trading 4.35 per cent down in early afternoon trade, currently worth 33 cents each in a $26.74 million market cap.

PIQ by the numbers
More From The Market Herald
(ASX:ATH) -

" Alterity Therapeutics (ASX:ATH) expands clinical development program

Alterity Therapeutics (ATH) is expanding the phase two clinical development program for its lead asset ATH434 in patients with Multiple System Atrophy (MSA).
Althea Group (ASX:AGH) - CEO, Joshua Fegan

" Althea Group (ASX:AGH) hits new high in sales receipts

Althea Group (AGH) brought in a new high of $4.5 million in customer receipts over the recently completed September quarter.
Singular Health Group (ASX:SHG) - Chief Operating Officer, James Hill

" Singular Health (ASX:SHG) collaborates with CSIRO and Osteopore (ASX:OSX)

Singular Health Group (SHG) will collaborate with CSIRO and Osteopore (OSX) for an artificial intelligence (AI) based tool to make patient-specific 3D cranial
ImpediMed (ASX:IPD) - MD and CEO, Richard Carreon

" ImpediMed (ASX:IPD) completes lymphoedema prevention trial

ImpediMed (IPD) has rounded off its PREVENT trial, successfully meeting its primary end point.